SCHEMBL2171135

SCHEMBL2171135

NCCCCc1ccc(Br)nc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 5/20 0.49
MAOA P21397 1/20 0.45
CYP2A6 P11509 1/20 0.43
CYP11B1 P15538 1/20 0.40
NPC1 O15118 1/20 0.39
NFKB1 P19838 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTR2A P28223 3/20 0.38
TAAR1 Q96RJ0 1/20 0.38
AKT2 P31751 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1871522 0.92 CYP2A6 (0.47) HRH1MAOACYP2A6CYP11B1NPC1
SCHEMBL10483953 0.87 CA12 (0.41) HRH1SMN1; SMN2
SCHEMBL1585757 0.86 TAAR1 (0.52) CYP2A6CYP11B1SMN1; SMN2L3MBTL1HTR2A
SCHEMBL10484115 0.84 SIGMAR1 (0.39) HRH1CYP2A6
Hydrochloric Acid SCHEMBL2714671 0.84 TAAR1 (0.50) CYP2A6CYP11B1MAPK1SMN1; SMN2L3MBTL1
SCHEMBL20576042 0.82 CYP11B1 (0.41) CYP11B1NPC1NFKB1MAPK1RAB9A
SCHEMBL10483902 0.82 CYP11B1 (0.41) CYP11B1NPC1NFKB1MAPK1RAB9A
SCHEMBL18354283 0.82 CYP11B1 (0.41) CYP2A6CYP11B1NPC1NFKB1MAPK1
SCHEMBL26394418 0.81 RAB9A (0.54) NPC1NFKB1MAPK1RAB9ANFKB2
SCHEMBL1874065 0.81 CA2 (0.41) CYP11B1NPC1NFKB1MAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346868-A1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-27 EP disclosed
WO-2010036632-A1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed